Alisia Dawn Stevens, OT | |
4820 Bandana Road, Bandana, KY 42022 | |
(270) 224-2065 | |
Not Available |
Full Name | Alisia Dawn Stevens |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | 4820 Bandana Road, Bandana, Kentucky |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003931809 | NPI | - | NPPES |
133572 | Other | KY | KENTUCKY STATE LICENSE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 133572 (Kentucky) | Primary |
Mailing Address | Practice Location Address |
---|---|
Alisia Dawn Stevens, OT Po Box 33, 4820 Bandana Road, Bandana, KY 42022-0033 Ph: (270) 224-2065 | Alisia Dawn Stevens, OT 4820 Bandana Road, Bandana, KY 42022 Ph: (270) 224-2065 |
News Archive
A new study by a Florida State University researcher reveals that a new dietary supplement is superior to calcium and vitamin D when it comes to bone health.
An international research collaboration led by Mayo Clinic has identified a new gene involved in causing the inherited kidney disorder, Meckel-Gruber syndrome (MKS). Children with MKS have central nervous system deformities as well as abnormal cysts in their kidneys, and usually die shortly after birth.
Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the closing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares.
Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration had granted tentative approval of adenosine injection, USP, the generic equivalent of Astellas Pharmaceuticals' Adenoscan®, in 60 mg per 20 mL and 90 mg per 30 mL vials. IMS data indicate that the 2009 U.S. innovator market for these adenosine presentations approximated $124 million. The Company plans to launch the product upon expiry of applicable innovator patents.
› Verified 1 days ago